ImmunityBio Investors Urged to Lead Suit Over Anktiva Promotion Claims

Overview

• Plaintiff firms issued fresh notices Friday inviting shareholders to seek lead-plaintiff status by May 26 in Douglas v. ImmunityBio, No. 2:26-cv-03261, in the Central District of California.
• The securities class action, already filed, accuses ImmunityBio and its executive chairman of violating the Securities Exchange Act through false or unsupported statements about the company’s lead drug, Anktiva.
• Complaints point to the FDA’s March 13 warning letter to CEO Richard Adcock, which found a TV ad and a podcast misbranded Anktiva by suggesting it could "cure and even prevent all cancer."
• Following broad publication of the FDA letter on March 24, ImmunityBio’s shares fell about 21% to close at $7.42, according to the investor notices.
• The proposed class covers buyers of ImmunityBio stock from January 19 through March 24, 2026, and firms including Robbins Geller, Kessler Topaz, and The Gross Law Firm are offering free case reviews for affected investors.